← Back to Search

Unknown

BAY2413555 Dose 2 for Chronic Heart Failure (REMOTE-HF Trial)

Phase 1
Waitlist Available
Research Sponsored by Bayer
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Summary

This trial is testing a new medicine called BAY2413555 to help people with chronic heart failure. The study will compare the safety and effects of BAY2413555 in patients who have special heart devices. Researchers hope this new medicine will protect the heart and improve its function.

Eligible Conditions
  • Chronic Heart Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: Treatment arm 2Experimental Treatment2 Interventions
Participants will receive BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
Group II: Treatment arm 1Experimental Treatment1 Intervention
Participants will receive BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).
Group III: PlaceboPlacebo Group1 Intervention
Participants will receive placebo to BAY2413555 for 28 days (Part A: 14 days and Part B: 14 days).

Find a Location

Who is running the clinical trial?

BayerLead Sponsor
2,260 Previous Clinical Trials
25,309,423 Total Patients Enrolled
~8 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top